Cargando…

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

INTRODUCTION: CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Katsuhiro, Ishida, Mitsuaki, Yanai, Hirotsugu, Tsuta, Koji, Sekimoto, Mitsugu, Sugie, Tomoharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195407/
https://www.ncbi.nlm.nih.gov/pubmed/34115802
http://dx.doi.org/10.1371/journal.pone.0253176
_version_ 1783706496336396288
author Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
author_facet Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
author_sort Yoshikawa, Katsuhiro
collection PubMed
description INTRODUCTION: CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. METHODS: Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73–10 assays), was also examined. RESULTS: CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73–10 assay did not show a correlation (p = 0.115). Using the 73–10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively). CONCLUSIONS: CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy.
format Online
Article
Text
id pubmed-8195407
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-81954072021-06-21 Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients Yoshikawa, Katsuhiro Ishida, Mitsuaki Yanai, Hirotsugu Tsuta, Koji Sekimoto, Mitsugu Sugie, Tomoharu PLoS One Research Article INTRODUCTION: CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. METHODS: Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73–10 assays), was also examined. RESULTS: CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73–10 assay did not show a correlation (p = 0.115). Using the 73–10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively). CONCLUSIONS: CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy. Public Library of Science 2021-06-11 /pmc/articles/PMC8195407/ /pubmed/34115802 http://dx.doi.org/10.1371/journal.pone.0253176 Text en © 2021 Yoshikawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
title Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
title_full Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
title_fullStr Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
title_full_unstemmed Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
title_short Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
title_sort immunohistochemical analysis of cd155 expression in triple-negative breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195407/
https://www.ncbi.nlm.nih.gov/pubmed/34115802
http://dx.doi.org/10.1371/journal.pone.0253176
work_keys_str_mv AT yoshikawakatsuhiro immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients
AT ishidamitsuaki immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients
AT yanaihirotsugu immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients
AT tsutakoji immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients
AT sekimotomitsugu immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients
AT sugietomoharu immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients